title: Translational research in neurology and neuroscience 2010: multiple sclerosis.
abstract: Over the past 2 decades, enormous progress has been made with regard to pharmacotherapies for patients with multiple sclerosis. There is perhaps no other subspecialty in neurology in which more agents have been approved that substantially alter the clinical course of a disabling disorder. Many of the pharmaceuticals that are currently approved, in clinical trials, or in preclinical development were initially evaluated in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis. Two Food and Drug Administration-approved agents (glatiramer acetate and natalizumab) were developed using the experimental autoimmune encephalomyelitis model. This model has served clinician-scientists for many decades to enable understanding the inflammatory cascade that underlies clinical disease activity and disease surrogate markers detected in patients.
authors.affiliation: Neurology Section, VA North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA. olaf.stuve@utsouthwestern.edu
authors.forename: Olaf
authors.initials: O
authors.lastname: Stüve
authors.forename: Bernd C
authors.initials: BC
authors.lastname: Kieseier
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hemmer
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Hartung
authors.forename: Amer
authors.initials: A
authors.lastname: Awad
authors.forename: Elliot M
authors.initials: EM
authors.lastname: Frohman
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Greenberg
authors.forename: Michael K
authors.initials: MK
authors.lastname: Racke
authors.forename: Scott S
authors.initials: SS
authors.lastname: Zamvil
authors.forename: J Theodore
authors.initials: JT
authors.lastname: Phillips
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
authors.forename: Andrew
authors.initials: A
authors.lastname: Chan
authors.forename: Uwe
authors.initials: U
authors.lastname: Zettl
authors.forename: Ron
authors.initials: R
authors.lastname: Milo
authors.forename: Ellen
authors.initials: E
authors.lastname: Marder
authors.forename: Omar
authors.initials: O
authors.lastname: Khan
authors.forename: Todd N
authors.initials: TN
authors.lastname: Eagar
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004195:Disease Models, Animal; D055808:Drug Discovery; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D000068717:Glatiramer Acetate; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D010455:Peptides / Q000627:therapeutic use*; D057170:Translational Research, Biomedical
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D010455:Peptides; D000068717:Glatiramer Acetate